• Leon, G., Gonzalez-Pier, E., Kanavos, P., Ruiz de Castilla, E. & Machinicki, G. (2024). The 30-Billion-Dollar Distribution Markups and Taxes of Pharmaceuticals in Latin American Countries: Impact, Options, and Trade-Offs. Value in Health Regional Issues, 44, 101015.
•  Leon, G., Carbonel, C., Rampuria, A., Rajpoot, R., Joshi, P. & Kanavos, P. (2024). An assessment of the implications of distribution remuneration and taxation policies on the final price of prescription medicines: evidence from 35 countries. The European Journal of Health Economics, 1-24
• Augustovski, F., Colaci, C., Mills, M., Chavez, D., Argento, F., Alfie, V., Riviere, A. P., Kanavos, P., & Alcaraz, A. (2024). A Systematic Review of Value Criteria for Next-Generation Sequencing/Comprehensive Genomic Profiling to Inform Value Framework Development. Value in Health. 

• Mills, M., Kanavos, P. (2023). Healthcare Payer Perspectives on the Assessment and Pricing of Oncology Multi-Indication Products: Evidence from Nine OECD Countries. PharmacoEconomics Open, 7, 553–565.

• Fontrier, AM., Kamphuis, B. & Kanavos, P. (2023). How can health technology assessment be improved to optimise access to medicines? Results from a Delphi study in Europe. Eur J Health Econ. 
• Main, C., Haig, M., Chavez, D., & Kanavos, P. (2023). Assessing the Value of Provider-Facing Digital Health Technologies Used in Chronic Disease Management: Toward a Value Framework Based on Multistakeholder Perceptions. Medical Decision Making, 44(1): 28-41.
• Angelis, A., Montibeller, G., & Kanavos, P. (2023). A structured methodology for essential medicines lists and health emergency stockpiles: Experience with the Emergency Medicines Buffer Stock in the United Kingdom. Social Science & Medicine, 337, 116236. 
• Haig, M., Main, C., Chavez, D. & Kanavos, P. (2023). A Value Framework to Assess Patient-Facing Digital Health Technologies That Aim to Improve Chronic Disease Management: A Delphi Approach. Value in Health , 26(10), 1474-1484.
• Apostolou, E. A., Fontrier, A., Efthimiadis, G. K., Kastritis, E., Parissis, J., & Kanavos, P. (2023). The patient pathway in ATTR-CM in Greece and how to improve it: A multidisciplinary perspective. Hellenic Journal of Cardiology, 73, 73-80. 
• Kanavos, P., & Vandoros, S. (2023). Road traffic mortality and economic uncertainty: Evidence from the United States. Social Science & Medicine, 326, 115891.
• Kanavos, P., Visintin, E., & Gentilini, A. (2023). Algorithms and heuristics of health technology assessments: A retrospective analysis of factors associated with HTA outcomes for new drugs across seven OECD countries. Social Science & Medicine, 331, 116045. 

• Mills, M. (2023). HTA Barriers for Conditional Approval Drugs. PharmacoEconomics, 41(5): 529-545. 
  

• Mills M, Michaeli D, Miracolo A, Kanavos P. (2023). Launch sequencing of pharmaceuticals with multiple therapeutic indications: evidence from seven countries. BMC Health Services Research, 23, 150.

• Kamphuis, B. W. & Kanavos, P. (2021). Assessing pricing and reimbursement policies for generic pharmaceuticals in the MENA region for improved efficiency, affordability and generic penetration. Health Policy OPEN 2, 100045. 
• Efthymiadou, O. & Kanavos, P. (2021). Determinants of Managed Entry Agreements in the context of Health Technology Assessment: a comparative analysis of oncology therapies in four countries. International Journal of Technology Assessment in Health Care, 37(1), e31. 

• Mills, M., & Kanavos, P. (2020). Do pharmaceutical budgets deliver financial sustainability in healthcare? Evidence from Europe. Health Policy, 124(3), 239–251. 
• Angelis, A., Kanavos, P. & Philips L.D. (2020). ICER Value Framework 2020 Update: recommendations on the aggregation of benefits and contextual considerations, Value in Health 23 (8), 1040 1048.  
• Kanavos, P., Fontrier, A-M., Gill, J. & Efthymiadou, O. (2020). Does external reference pricing deliver what it promises? Evidence on its impact at national level. The European Journal of Health Economics, 21(1), 129–151. 
• Kanavos, P., Kamphuis, B.W., Fontrier A-M., Colville Parkin, G., Saleh, S. & Ahkras, K.S. (2020). Pricing of in-patent pharmaceuticals in the Middle East and North Africa: Is external reference pricing implemented optimally?Health Policy, 124(12), 1297–1309. 
• Miracolo, A., Sophiea, M., Mills, M. & Kanavos, P. (2020). The impact of sin taxes on consumption, revenue generation and health improvement: A systematic literature review in Latin America. Health Policy and Planning, 36(5), 790–810

• Fontrier, A.M., Gill, J. & Kanavos, P. (2019). International impact of external reference pricing: should national policy-makers care?. The European Journal of Health Economics, 20(8), pp.1147-1164.
• Gill, J., Fontrier, A.-M., Kyriopoulos, D., & Kanavos, P. (2019). Variations in external reference pricing implementation: Does it matter for public policy?The European Journal of Health Economics, 20(9), 1375–1397. 
• Kanavos, P., Angelis, A., & Drummond, M. (2019). An EU-wide approach to HTA: An irrelevant development or an opportunity not to be missed?.The European journal of health economics : HEPAC : health economics in prevention and care, 20(3), 329–332. 
• Visintin, E., Tinelli, M., & Kanavos, P. (2019). Value assessment of disease-modifying therapies for Relapsing-Remitting Multiple Sclerosis: HTA evidence from seven OECD countries.Health Policy, 123(2), 118–129. 

• Angelis, A., Lange, A. & Kanavos, P. (2018). Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries. The European Journal of Health Economics, 19(1), 123–152. 
• Efthymiadou, O., Mossman, J. & Kanavos, P. (2018). Health Related Quality of Life aspects not captured by EQ- 5D-5L: Results from an international survey of patients. Health Policy. 123(2):159-165.  .
• Efthymiadou, O., Kanavos, P. & Mossman, J. (2018). Differentiation of Health-Related Quality of Life outcomes between five disease areas; results from an international survey of patients. International Journal of Technology Assessment in Health Care, 34(5), 498–506. 
• Tinelli, M., Kanavos, P., Efthymiadou, O., Visintin, E., Grimaccia, F. & Mossman, J. (2018). Using IMPrESS to guide policy change in multiple sclerosis. Multiple Sclerosis. 24(9), 1251–1255. 
• Gill, J., Baiceanu, A., Clark, P. J., Langford, A., Latiff, J., Yang, P.-M., Yoshida, E. M., & Kanavos, P. (2018). Insights into the hepatocellular carcinoma patient journey: Results of the first global quality of life survey. Future Oncology, 14(17), 1701–1710. 

• Angelis, A., Montibeller, G., Hochhauser, D. & Kanavos P. (2017). Multiple criteria decision analysis in the context of health technology assessment: a simulation exercise on metastatic colorectal cancer with multiple stakeholders in the English setting. BMC Medical Informatics and Decision Making, 17, 149. 
• Angelis, A., & Kanavos, P. (2017). Multiple Criteria Decision Analysis (MCDA) for evaluating new medicines in Health Technology Assessment and beyond: The Advance Value Framework. Social Science & Medicine, 188, 137–156. 
• Angelis, A., Tordrup, D. & Kanavos, P. (2017). Is the funding of public national health systems sustainable over the long term? Evidence from eight OECD countries. Global Policy, 8(S2), 7–22. 
• Gill, J., & Kanavos, P. (2017). RWE in Europe – An Analysis. Journal of Health Policy and Outcomes Research, 2/2017. 

• Gill, J., Chavez, D., Main, C., Miracolo, A. & Kanavos, P. (2024). Sustainable Healthcare Financing for SDG3 in ASEAN-6. The London School of Economics and Political Science, London, UK.

• Gill, J., Miracolo, A., Politopoulou, K., Jayawardana, S., Apostolou, E., Carter, A. and Kanavos, P. (2023). Determining the Benefits of Improving Secondary Prevention of Cardiovascular Disease. The London School of Economics and Political Science, London, UK.

• Main, C., Haig, M., & Kanavos, P. (2022). The promise of population health management in England: from theory to implementation. The London School of Economics and Political Science, London, UK.
• Efthymiadou, O., Kamphuis, B., Gill, J., Haig, M., & Kanavos, P. (2022). Towards better outcomes in autism by addressing policy change. The London School of Economics and Political Science, London, UK.
• Kamphuis, B.W., Fontrier, A-M., Haig, M., Politopoulou, K., Salyga, H., Gentilini, A., & Kanavos, P. (2022). Development of policies to increase headroom for innovation in Egypt and the Kingdom of Saudi Arabia. The London School of Economics and Political Science, London, UK.

• Kamphuis, B.W., Fontrier, A-M., Efthymiadou, O., Gill, J., Salyga, H., & Kanavos, P. (2021). Access to medicines in Europe: Delays and challenges for timely patient access. The London School of Economics and Political Science, London, UK.  
• Kamphuis, B.W., Fontrier, A-M., Efthymiadou, O., Gill, J., Salyga, H., & Kanavos, P. (2021). Access to medicines in Europe: Delays and challenges for timely patient access. The London School of Economics and Political Science, London, UK.  
• Kamphuis, B.W., Gill, J., Vogelzang, M., Haig, M. & Kanavos, P. (2021). The Role of Virtual Health Care and the Pharmaceutical Sector in Improving Population Health. The London School of Economics and Political Science, London, UK.  
• Miracolo, A., Mills, M., & Kanavos, P. (2021). Predictive Analytic Tools and Value Based Healthcare.The London School of Economics and Political Science, London, UK.
• Kamphuis B.W., Efthymiadou, O., Tzouma, V. & Kanavos, P. (2021). Severe asthma care and treatment: Indicators and data for performance management across ten countries. The London School of Economics and Political Science, London, UK.
• Efthymiadou, O., Kamphuis B.W., Tzouma, V. & Kanavos, P. (2021). Treatment gaps in severe asthma across nine OECD countries and recommendations for addressing them: An international survey of clinicians. The London School of Economics and Political Science, London, UK.
• (2021). MSD Global Oncology Policy 2019 Grants Program: Report of the Inaugural Forum. The London School of Economics and Political Science, London, UK.
• Vogelzang, M., Haig, M. & Kanavos, P. (2021). The Role of Virtual Health Care and the Pharmaceutical Sector in Improving Population Health. The London School of Economics and Political Science, London, UK.  
• Miracolo, A., Mills, M., & Kanavos, P. (2021). Predictive Analytic Tools and Value Based Healthcare. The London School of Economics and Political Science, London, UK.
• Kamphuis B.W., Efthymiadou, O., Tzouma, V. & Kanavos, P. (2021). Severe asthma care and treatment: Indicators and data for performance management across ten countries. The London School of Economics and Political Science, London, UK.
• Efthymiadou, O., Kamphuis B.W., Tzouma, V. & Kanavos, P. (2021). Treatment gaps in severe asthma across nine OECD countries and recommendations for addressing them: An international survey of clinicians. The London School of Economics and Political Science, London, UK.
• (2021). MSD Global Oncology Policy 2019 Grants Program: Report of the Inaugural Forum. The London School of Economics and Political Science, London, UK.

Gill, J., Fontrier, A-M., Miracolo, A. & Kanavos, P. (2020). Access to Personalised Oncology in Europe. The London School of Economics and Political Science, London, UK.

• Kanavos, P., Colville Parkin, G., Kamphuis, B.W. & Gill, J. (2019). Latin America Healthcare System Overview: A comparative analysis of fiscal space in healthcare. The London School of Economics and Political Science, London, UK.
• Mills, M., Zhang, A. & Kanavos, P. (2019). Pharmaceutical Policy in China. The London School of Economics and Political Science, London, UK.

• Kanavos, P. & Mossman, J. (2018). Changing Paradigms in the Management of Multiple Sclerosis. The London School of Economics and Political Science, London, UK.
• Kamphuis, B.W. et al. (2018). Policy Challenges around Real World Evidence Adoption in Europe. The London School of Economics and Political Science, London, UK.
• Gill, J. et al. (2018). Engaging Pharma in the RWE Roadmap. The London School of Economics and Political Science, London, UK.
• Kanavos, P., Tzouma, V., Fontrier, A-M., Kamphuis, B.W., Colville Parkin, G., & Saleh, S. (2018). Pharmaceutical Pricing and Reimbursement in the Middle East and North Africa Region: A Mapping of the Current Landscape and Options for the Future. The London School of Economics and Political Science, London, UK.
• Kanavos, P., Tzouma, V., Efthymiadou, O., Mills, M., & Flannelly, C. (2018). Accelerated Approval and Access Schemes: A mapping of policies across the globe and the impact of accelerated approval on the HTA of new oncology medicines. The London School of Economics and Political Science, London, UK.

• Gill, J. et al. (2017). A Roadmap for RWE. The London School of Economics and Political Science, London, UK. 
• Gill, J. et al. (2017). The Use of Real World Evidence in the Disease Context. The London School of Economics and Political Science, London, UK.
• Kanavos, P.,  Fontrier, A-M., Gill, J., Efthymiadou, O., & Boekstein, N. (2017). The Impact of External Reference Pricing within and across Countries. The London School of Economics and Political Science, London, UK.

• Gill, J. et al. (2016). The Use of Real World Evidence in the European Context. The London School of Economics and Political Science, London, UK.
• Kanavos, P., Tinelli, M., Efthymiadou, O., Visintin, E., Grimaccia, F., & Mossman, J. (2016). Towards better outcomes in multiple sclerosis by addressing policy change: the International MultiPlE Sclerosis Study (IMPrESS). The London School of Economics and Political Science, London, UK.

• Tinelli, M. & Kanavos, P. (2015). Cost and Impact of Non-Treating Severe Mental Illnesses (SMIs): The Case Study of Schizophrenia. The London School of Economics and Political Science, London, UK.